Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
76-90 of 249
Cracking the Migraine Code: How AI May Transform Diagnosis and Treatment
On the Frontlines of MigraineCracking the Migraine Code: How AI May Transform Diagnosis and Treatment
Ashley Baker, MSN, PMHNP
Chia-Chun Chiang, MD
Challenges and Opportunities in Migraine Management
On the Frontlines of MigraineChallenges and Opportunities in Migraine Management
Charles Turck, PharmD, BCPS, BCCCP
Yulia Orlova, MD
Endogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems
On the Frontlines of MigraineEndogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems
Ashley Baker, MSN, PMHNP
Adriana Della Pietra, MD
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Alexandria May, PharmD, BCPS
Nicholas Whipple, MD, MPH
How Daily Light Habits Influence Migraine in Adolescents
On the Frontlines of MigraineHow Daily Light Habits Influence Migraine in Adolescents
Charles Turck, PharmD, BCPS, BCCCP
Carlyn Patterson Gentile, MD
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
NeuroFrontiersBridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
Ashvini Keshavan, MRCP, PhD
- advertisement
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
On the Frontlines of SchizophreniaNegative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Brian P. McDonough, MD, FAAFP
Ahmed Makhlouf, MD
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Hamid Abuwarda, PhD, BS
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Sharon Sha, MD, MS
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
- advertisement
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's RoundtableLinking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Stephen Wong, PhD
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CEAre All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Christoph U. Correll, MD
Jonathan M. Meyer
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
